HopeStage
Back to all studies
CompletedNCT01503359

Sarcosine or Placebo for Schizophrenia Symptoms and Well-Being

About this titleRead the official source — NCT01503359
Placebo comparisonAges 18–60Poland
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2012
Recruitment status
Completed
Enrollment listed in the registry
70
Sponsor
Medical University of Lodz
Sponsor type
University
Study type
Other
Intervention type
Dietary supplement
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Poland
Age range
From 18 Years to 60 Years
Official registry ID
NCT01503359
Official title
Show the full official title

Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Lodz

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Medical University of Lodz, a university.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies